Cathepsin L (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Cathepsin L (CTSL; UniProt P07711), expressed in HEK293 cells. Suitable for enzymatic activity assays, cysteine protease inhibitor screening, substrate cleavage studies, and antibody validation.
Expression system
HEK293
Cat. #
REC-CathepsinL

In stock

SKU
REC-CathepsinL
$498.00

Target Overview

Cathepsin L (CTSL; UniProt P07711) is a lysosomal cysteine endopeptidase of the papain superfamily, encoded by the CTSL gene. The full-length human precursor (procathepsin L) is 333 amino acids and undergoes stepwise autocatalytic and trans-processing to yield a mature two-chain active enzyme. This recombinant is produced in HEK293 mammalian cells, providing human-compatible glycosylation patterns and correctly folded active-site geometry — properties important for faithful kinetic characterisation and inhibitor profiling compared with bacterial or insect-cell preparations. In the research setting, recombinant Cathepsin L is most commonly deployed in fluorogenic peptide-substrate cleavage assays (e.g., Z-Phe-Arg-AMC), where initial velocity measurements at defined pH and reducing conditions establish specific activity and permit IC50 determination for candidate inhibitors. It is equally used as a positive-control antigen for Western blot and immunohistochemical validation of anti-CTSL antibodies; researchers using this recombinant for antibody validation can pair it with the matched Triple Point Biologics anti-Cathepsin L antibody (SKU: RP-CathepsinL), which has been validated for Western blot against human CTSL. The HEK293 expression format is particularly suited to studies requiring intact pro-domain processing intermediates or investigations of secreted versus lysosomal trafficking, since the mammalian secretory pathway is preserved. The enzyme's documented activity against elastin at neutral pH and its role in extracellular matrix remodelling also make this recombinant useful in gelatin and collagen degradation assays beyond classical lysosomal substrate panels.

Background

Cathepsin L is a ubiquitously expressed lysosomal cysteine protease that plays a central role in general protein turnover, antigen presentation, and selective extracellular matrix remodelling. Within the endolysosomal compartment it degrades a broad spectrum of substrates, contributes to MHC class II peptide loading in cortical thymic epithelial cells, and mediates proenkephalin processing in neuroendocrine vesicles. A secreted form has been shown to generate endostatin through proteolytic processing of collagen XVIII (COL18A1), demonstrating activity well outside the lysosomal lumen. In published research, Cathepsin L has been studied as a research target across several disease-relevant contexts. Kumar V et al. (J Med Chem, 2026; PMID 42014929) characterised peptidomimetic α,β-unsaturated ethyl esters as irreversible inactivators of human Cathepsin L, employing recombinant enzyme in kinetic inactivation assays and demonstrating potent activity against SARS-CoV-2 in cellular infection models — an example of the enzyme's established role as a host-cell entry protease for coronaviruses. Separately, Lumi Tanaka Dino C et al. (Tissue Barriers, 2026; PMID 41319265) explored Cathepsin L-dependent alternative entry pathways for SARS-CoV-2 at the placental interface, underscoring the enzyme's mechanistic relevance in viral tropism studies. Beyond virology, Park SY et al. (Nat Commun, 2025; PMID 41315185) investigated Cathepsin L as a dual research target in the context of cancer-associated muscle wasting and PD-L1-directed immunotherapy, identifying the enzyme as a mediator at the interface of tumour biology and skeletal muscle catabolism. Han Y et al. (Nat Commun, 2025; PMID 41290598) demonstrated that lysosomal Cathepsin L activates eosinophils through ARG1-mediated arginine metabolism in allergic airway inflammation models, expanding the enzyme's characterised roles into innate immune regulation. In oncology, Shi H et al. (Mol Cell Biochem, 2026; PMID 41182650) reported that Cathepsin L promotes stemness and multidrug resistance in non-small cell lung cancer by targeting HGF activator, a finding that positions recombinant CTSL as a useful reagent for substrate-identification experiments in cancer biology. Collectively, these published findings reflect the breadth of in vitro and cellular systems in which recombinant Cathepsin L is actively applied — from covalent inhibitor development and viral entry mechanistics to tumour microenvironment and immune cell biology.

Applications

  • Fluorogenic peptide-substrate (Z-Phe-Arg-AMC) cleavage assay to determine specific enzymatic activity
  • Inhibitor IC50 and kinact/KI determination for cysteine protease drug candidates
  • Irreversible inactivator characterisation by jump-dilution and mass spectrometry active-site labelling
  • Antibody validation positive control on Western blot and IHC (pairs with TP SKU RP-CathepsinL)
  • Gelatin and extracellular matrix degradation assays at neutral and acidic pH
  • Viral spike protein processing studies as a host-cell entry protease model
  • Substrate identification and cleavage-site mapping by mass spectrometry-based degradomics
  • Steady-state and pre-steady-state kinetic characterisation of cysteine protease mechanism

References

  1. Kumar V et al. Peptidomimetic α,β-Unsaturated Ethyl Esters Are Irreversible Inactivators of Human Cathepsin L and Are Potent Inhibitors of SARS-CoV-2 in Cellular Models of COVID-19. J Med Chem. 2026. doi:10.1021/acs.jmedchem.5c03172. PMID: 42014929.
  2. Lumi Tanaka Dino C et al. Placental infection by SARS-CoV-2: exploring alternative entry pathways. Tissue Barriers. 2026. doi:10.1080/21688370.2025.2585246. PMID: 41319265.
  3. Park SY et al. Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1. Nat Commun. 2025. doi:10.1038/s41467-025-64500-0. PMID: 41315185.
  4. Han Y et al. Lysosomal acidity and cathepsin L activate eosinophils via ARG1-mediated arginine metabolism in allergic airway inflammation. Nat Commun. 2025. doi:10.1038/s41467-025-65400-z. PMID: 41290598.
  5. Shi H et al. The lysosomal cysteine protease cathepsin L promotes stemness and multidrug resistance of non-small cell lung cancer by targeting HGF activator. Mol Cell Biochem. 2026. doi:10.1007/s11010-025-05423-8. PMID: 41182650.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight does recombinant Cathepsin L run at on SDS-PAGE under reducing conditions?

Under reducing SDS-PAGE, this HEK293-expressed recombinant resolves as two predominant bands: the heavy chain (~25 kDa) and the light chain (~5 kDa) of the processed mature two-chain form, plus a variable proportion of single-chain intermediate (~38 kDa) depending on processing completeness. Under non-reducing conditions, the disulfide-linked two-chain form migrates near 30–32 kDa. Purity is >95% by SDS-PAGE. If you see only the ~38 kDa band, mild acid pre-incubation (pH 5.5, 37°C, 30 min) can drive further autocatalytic maturation before your assay.

What processing form is this recombinant Cathepsin L — procathepsin, single-chain, or mature two-chain?

The recombinant is supplied predominantly as the mature active enzyme, with the propeptide removed via autocatalytic and trans-processing during HEK293 production. You will typically observe a mixture of the mature two-chain form (heavy chain ~25 kDa + light chain ~5 kDa) and some single-chain intermediate (~38 kDa). Both forms carry active-site Cys25/His163 geometry and are enzymatically competent. If your downstream application requires a homogeneous single form, size-exclusion chromatography at pH 5.5 under reducing conditions can enrich the fully processed species.

What substrates does Cathepsin L cleave and what is its preferred cleavage specificity?

Cathepsin L is a papain-family cysteine endopeptidase with a strong preference for hydrophobic residues (Phe, Leu, Val) at the P2 position. The canonical fluorogenic substrate for activity assays is Z-Phe-Arg-AMC (ex/em 355/460 nm), which Cathepsin L cleaves with Km in the low-micromolar range (~10–20 µM under standard conditions). It also processes Z-Leu-Arg-AMC, though with lower efficiency. Physiological substrates include extracellular matrix components (fibronectin, laminin), MHC class II-associated invariant chain, and several pro-hormones. Cathepsin B and L activities can be discriminated using the selective inhibitor CA-074 to block Cathepsin B before measuring residual Z-Phe-Arg-AMC turnover.

What buffer and pH conditions should I use for a Cathepsin L fluorogenic activity assay with Z-Phe-Arg-AMC?

Optimal activity is at pH 5.5–6.0. A standard assay buffer is 50 mM sodium acetate pH 5.5, 4 mM EDTA, 8 mM DTT (or 2 mM TCEP); pre-incubate enzyme in reducing buffer for 10–15 min at 37°C before adding substrate to ensure full active-site thiol reduction. Use Z-Phe-Arg-AMC at 10–50 µM final concentration in a total volume of 100–200 µL. Note: the storage buffer for this recombinant is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — buffer-exchange or dilute ≥10-fold into assay buffer to avoid pH interference.

What starting concentration of recombinant Cathepsin L should I use for IC50 inhibitor profiling?

For IC50 determinations, use 0.5–2 nM active enzyme in assay buffer (50 mM sodium acetate pH 5.5, 4 mM EDTA, 8 mM DTT) with Z-Phe-Arg-AMC at a concentration near the Km (~20 µM). Keeping enzyme well below substrate Km minimises tight-binding artefacts. For jump-dilution or pre-incubation experiments probing covalent inhibitors, a 10-fold pre-incubation concentration (5–20 nM) followed by 10-fold dilution into substrate is practical. Verify linear progress curves for at least 30 min before adding inhibitor series; significant curvature indicates substrate depletion or enzyme instability.

Can I use this recombinant Cathepsin L as a positive control for Western blot with the TPB anti-Cathepsin L antibody?

Yes — this is one of the primary intended uses. Load 10–50 ng of recombinant Cathepsin L per lane on a 12–15% SDS-PAGE gel run under reducing conditions. The matched antibody, RP-CathepsinL (/anti-cathepsin-l-rabbit-polyclonal-antibody), is a rabbit polyclonal raised against human Cathepsin L and is validated for Western blot by Triple Point Biologics. It reliably detects both the ~38 kDa single-chain and the ~25 kDa heavy-chain bands. Starting dilution of RP-CathepsinL for WB is 1:1,000–1:5,000; titrate down if background is high in your lysate matrix.

How much recombinant Cathepsin L should I load as a positive control when validating the RP-CathepsinL antibody by Western blot?

Load 10–100 ng per lane; 25 ng is a practical starting point that gives a clean, quantifiable signal without saturating the film or CCD. Because the recombinant is >95% pure, this lane also serves as a molecular-weight reference: expect a strong band at ~25 kDa (mature heavy chain) and a fainter band at ~38 kDa (single-chain intermediate). Run alongside 20–40 µg of a CTSL-expressing cell lysate (e.g., HeLa or MCF-7) to confirm that RP-CathepsinL (SKU: RP-CathepsinL) detects the endogenous form at the same apparent MW.

How should I store and handle recombinant Cathepsin L to maintain activity — can I refreeze unused aliquots?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and is shipped on dry ice. Store at -20°C in the single-use aliquots provided; repeated freeze-thaw cycles progressively reduce specific activity due to thiol oxidation and aggregation. On the day of use, thaw one aliquot on ice, keep at 4°C, and use within 8 hours. For activity assays, pre-reduce the thawed enzyme (8 mM DTT, 10 min, 25°C) before diluting into assay buffer. Avoid diluting to <0.1 nM in the absence of a carrier protein (0.01% BSA helps stabilise low-concentration working stocks).

Validation imagery coming soon

Western blot validation figures for REC-CathepsinL will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →